Related Experiment Video

Updated: Jun 18, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Targeting translation in acute myeloid leukemia: a new paradigm for therapy?

Jerome Tamburini1, Alexa S Green, Nicolas Chapuis

  • 1Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France.

Cell Cycle (Georgetown, Tex.)
|November 26, 2009
PubMed

Insights

Targeting the mTORC1 pathway shows limited efficacy in acute myeloid leukemia (AML). New strategies inhibiting mRNA translation or using novel mTOR inhibitors offer promising therapeutic avenues for AML.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The mammalian Target Of Rapamycin Complex 1 (mTORC1) pathway is frequently activated in cancer, including acute myeloid leukemia (AML).
  • mTORC1 inhibitors (rapalogs) have shown limited efficacy in AML due to feedback activation of PI3K/ERK pathways and mTORC1-independent mRNA translation contributing to resistance.

Purpose of the Study:

  • To explore novel therapeutic strategies to overcome rapalogs resistance in AML.
  • To investigate the potential of targeting mRNA translation and using second-generation mTOR inhibitors for AML treatment.

Main Methods:

  • Review of current understanding of mTORC1 signaling and resistance mechanisms in AML.
  • Discussion of alternative therapeutic approaches including direct translation inhibition and novel mTOR inhibitors.

Main Results:

  • Feedback activation of PI3K/ERK pathways necessitates simultaneous targeting with mTORC1 inhibition for enhanced anti-leukemic activity.
  • mTORC1-independent mRNA translation is a significant driver of oncogenesis and resistance in AML.

Conclusions:

  • Targeting mRNA translation initiation (e.g., using 4EGI-1, anti-eIF4E ASOs, or ribavirin) presents a promising strategy.
  • Second-generation mTOR inhibitors (TORkinhibs) offer an alternative approach.
  • These novel strategies hold potential for future clinical development in AML therapy.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life